/**
 * Ofev (Boehringer Ingelheim) - Pre-Approved Content Library
 * Starter Pack: US and Germany Markets (15 entries)
 */

export const OfevPreApprovedContent = [
  // US Market - Efficacy Claims (3 entries)
  {
    id: 'ofev-us-eff-001',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'US',
    category: 'efficacy_claim',
    contentType: 'claim',
    therapeuticArea: 'Respiratory',
    approvedContent: 'OFEV reduced the annual rate of decline in FVC by approximately 50% compared to placebo in the INPULSIS trials (INPULSIS-1: -114.7 mL/year vs -239.9 mL/year; INPULSIS-2: -113.6 mL/year vs -207.3 mL/year).',
    usageGuidelines: 'Use for HCP communications only. Must be accompanied by fair balance and safety information.',
    restrictions: [
      'Cannot be used in direct-to-consumer advertising',
      'Must cite INPULSIS trials',
      'Requires ISI on same page or screen'
    ],
    mlrNumber: 'MLR-OFEV-2024-US-0045',
    approvalDate: '2024-01-15',
    expiryDate: '2025-01-15'
  },
  {
    id: 'ofev-us-eff-002',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'US',
    category: 'efficacy_claim',
    contentType: 'claim',
    therapeuticArea: 'Respiratory',
    approvedContent: 'In pooled analysis of INPULSIS trials, OFEV slowed disease progression in patients with IPF, reducing the risk of acute exacerbations.',
    usageGuidelines: 'Use for HCP email communications and medical education materials.',
    restrictions: [
      'Must include "as demonstrated in clinical trials" context',
      'Requires full ISI inclusion',
      'Cannot stand alone without supporting clinical data'
    ],
    mlrNumber: 'MLR-OFEV-2024-US-0067',
    approvalDate: '2024-02-10',
    expiryDate: '2025-02-10'
  },
  {
    id: 'ofev-us-eff-003',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'US',
    category: 'mechanism',
    contentType: 'mechanism_of_action',
    therapeuticArea: 'Respiratory',
    approvedContent: 'OFEV (nintedanib) is a tyrosine kinase inhibitor (TKI) that targets multiple receptor tyrosine kinases and non-receptor tyrosine kinases, including PDGF receptors, FGF receptors, and VEGF receptors.',
    usageGuidelines: 'Use in scientific communications, medical education, and HCP materials.',
    restrictions: [
      'Cannot oversimplify mechanism',
      'Must maintain scientific accuracy',
      'Suitable for all HCP audiences'
    ],
    mlrNumber: 'MLR-OFEV-2024-US-0023',
    approvalDate: '2023-11-20',
    expiryDate: '2025-11-20'
  },

  // US Market - Safety Information (3 entries)
  {
    id: 'ofev-us-safe-001',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'US',
    category: 'safety_info',
    contentType: 'safety_info',
    therapeuticArea: 'Respiratory',
    approvedContent: 'Most common adverse reactions (≥3% and more frequent than placebo) were diarrhea (62%), nausea (24%), abdominal pain (15%), vomiting (12%), liver enzyme elevation, decreased appetite, headache, weight decreased, and hypertension.',
    usageGuidelines: 'Must appear in all promotional materials. Can be abbreviated as "Most common adverse reactions..." in space-limited formats.',
    restrictions: [
      'Cannot minimize or omit diarrhea as most common AE',
      'Percentages must be exact as listed',
      'Must include "≥3% and more frequent than placebo" qualifier'
    ],
    mlrNumber: 'MLR-OFEV-2024-US-0089',
    approvalDate: '2024-01-05',
    expiryDate: '2025-01-05'
  },
  {
    id: 'ofev-us-safe-002',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'US',
    category: 'safety_info',
    contentType: 'safety_info',
    therapeuticArea: 'Respiratory',
    approvedContent: 'OFEV can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus and to avoid becoming pregnant while receiving OFEV.',
    usageGuidelines: 'Include in all HCP materials. Critical safety information.',
    restrictions: [
      'Cannot be minimized or placed in small print',
      'Must be clearly visible and prominent',
      'Required in all formats'
    ],
    mlrNumber: 'MLR-OFEV-2024-US-0091',
    approvalDate: '2024-01-05',
    expiryDate: '2025-01-05'
  },
  {
    id: 'ofev-us-safe-003',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'US',
    category: 'safety_info',
    contentType: 'safety_info',
    therapeuticArea: 'Respiratory',
    approvedContent: 'In clinical trials, gastrointestinal disorders were the most frequently reported adverse reactions. Diarrhea was manageable with dose modification and hydration.',
    usageGuidelines: 'Use to provide context on adverse event management in HCP communications.',
    restrictions: [
      'Must not minimize severity of diarrhea',
      'Include reference to dose modification option',
      'Cannot claim "easy to manage"'
    ],
    mlrNumber: 'MLR-OFEV-2024-US-0112',
    approvalDate: '2024-03-01',
    expiryDate: '2025-03-01'
  },

  // US Market - Disclaimers & Dosing (2 entries)
  {
    id: 'ofev-us-disc-001',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'US',
    category: 'disclaimer',
    contentType: 'disclaimer',
    therapeuticArea: 'Respiratory',
    approvedContent: 'Please see full Prescribing Information, including Patient Information. For Medical Information inquiries, call 1-800-542-6257 or visit www.ofev.com.',
    usageGuidelines: 'Include at bottom of all promotional materials, emails, and digital content.',
    restrictions: [
      'Must be clearly visible',
      'Cannot be smaller than 8pt font',
      'Required on every page/screen'
    ],
    mlrNumber: 'MLR-OFEV-2024-US-0001',
    approvalDate: '2023-12-01',
    expiryDate: '2025-12-01'
  },
  {
    id: 'ofev-us-dose-001',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'US',
    category: 'dosing_info',
    contentType: 'dosing_info',
    therapeuticArea: 'Respiratory',
    approvedContent: 'The recommended dosage of OFEV is 150 mg twice daily administered approximately 12 hours apart. For patients who do not tolerate the 150 mg dose, the dosage can be reduced to 100 mg twice daily.',
    usageGuidelines: 'Use exact wording from PI for dosing information. Cannot be modified.',
    restrictions: [
      'Cannot alter dosing instructions',
      'Must match package insert verbatim',
      'Include dose reduction option'
    ],
    mlrNumber: 'MLR-OFEV-2024-US-0008',
    approvalDate: '2023-12-15',
    expiryDate: '2025-12-15'
  },

  // Germany Market - Efficacy Claims (2 entries)
  {
    id: 'ofev-de-eff-001',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'Germany',
    category: 'efficacy_claim',
    contentType: 'claim',
    therapeuticArea: 'Respiratory',
    approvedContent: 'OFEV reduzierte die jährliche Rate des FVC-Rückgangs um etwa 50% im Vergleich zu Placebo in den INPULSIS-Studien (INPULSIS-1: -114,7 ml/Jahr vs. -239,9 ml/Jahr; INPULSIS-2: -113,6 ml/Jahr vs. -207,3 ml/Jahr).',
    usageGuidelines: 'Nur für Fachinformationen an medizinisches Fachpersonal. Muss mit Sicherheitsinformationen begleitet werden.',
    restrictions: [
      'Nicht für Patientenmaterialien geeignet',
      'Muss INPULSIS-Studien zitieren',
      'Fachinformation-Referenz erforderlich'
    ],
    mlrNumber: 'MLR-OFEV-2024-DE-0034',
    approvalDate: '2024-01-22',
    expiryDate: '2025-01-22'
  },
  {
    id: 'ofev-de-eff-002',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'Germany',
    category: 'indication',
    contentType: 'indication',
    therapeuticArea: 'Respiratory',
    approvedContent: 'OFEV ist indiziert zur Behandlung der idiopathischen Lungenfibrose (IPF) bei Erwachsenen.',
    usageGuidelines: 'Exakte Indikation gemäß Fachinformation. Keine Abweichungen erlaubt.',
    restrictions: [
      'Wortlaut darf nicht verändert werden',
      'Muss mit SmPC übereinstimmen',
      'Pflichtangabe in allen Materialien'
    ],
    mlrNumber: 'MLR-OFEV-2024-DE-0001',
    approvalDate: '2023-12-10',
    expiryDate: '2025-12-10'
  },

  // Germany Market - Safety & Disclaimers (3 entries)
  {
    id: 'ofev-de-safe-001',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'Germany',
    category: 'safety_info',
    contentType: 'safety_info',
    therapeuticArea: 'Respiratory',
    approvedContent: 'Häufigste Nebenwirkungen (≥3% und häufiger als unter Placebo): Durchfall (62%), Übelkeit (24%), Bauchschmerzen (15%), Erbrechen (12%), Erhöhung der Leberenzyme, verminderter Appetit, Kopfschmerzen, Gewichtsabnahme und Hypertonie.',
    usageGuidelines: 'Pflichtangabe in allen Werbematerialien. Kann in platzlimitierten Formaten abgekürzt werden.',
    restrictions: [
      'Durchfall als häufigste NW muss genannt werden',
      'Prozentangaben müssen exakt sein',
      'Muss "≥3% und häufiger als unter Placebo" enthalten'
    ],
    mlrNumber: 'MLR-OFEV-2024-DE-0078',
    approvalDate: '2024-01-18',
    expiryDate: '2025-01-18'
  },
  {
    id: 'ofev-de-disc-001',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'Germany',
    category: 'disclaimer',
    contentType: 'disclaimer',
    therapeuticArea: 'Respiratory',
    approvedContent: 'Bitte beachten Sie die vollständige Fachinformation (SmPC) für Verschreibungsinformationen. Für medizinische Anfragen kontaktieren Sie: +49 (0) 6132 77-0 oder medinfo.de@boehringer-ingelheim.com',
    usageGuidelines: 'Pflichtangabe am Ende aller Materialien für medizinisches Fachpersonal.',
    restrictions: [
      'Muss gut sichtbar sein',
      'Mindestens 8pt Schriftgröße',
      'Erforderlich auf jeder Seite'
    ],
    mlrNumber: 'MLR-OFEV-2024-DE-0002',
    approvalDate: '2023-12-12',
    expiryDate: '2025-12-12'
  },
  {
    id: 'ofev-de-dose-001',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'Germany',
    category: 'dosing_info',
    contentType: 'dosing_info',
    therapeuticArea: 'Respiratory',
    approvedContent: 'Die empfohlene Dosierung von OFEV beträgt 150 mg zweimal täglich im Abstand von ca. 12 Stunden. Bei Patienten, die die 150-mg-Dosis nicht vertragen, kann die Dosierung auf 100 mg zweimal täglich reduziert werden.',
    usageGuidelines: 'Exakter Wortlaut gemäß Fachinformation. Keine Änderungen erlaubt.',
    restrictions: [
      'Dosierungsanweisungen dürfen nicht geändert werden',
      'Muss mit Packungsbeilage übereinstimmen',
      'Dosisreduktionsoption muss erwähnt werden'
    ],
    mlrNumber: 'MLR-OFEV-2024-DE-0009',
    approvalDate: '2023-12-20',
    expiryDate: '2025-12-20'
  },

  // Germany Market - Mechanism (1 entry)
  {
    id: 'ofev-de-mech-001',
    brandId: '6fcf0fec-116f-46ff-ab6a-5ee70af9d36f',
    market: 'Germany',
    category: 'mechanism',
    contentType: 'mechanism_of_action',
    therapeuticArea: 'Respiratory',
    approvedContent: 'OFEV (Nintedanib) ist ein Tyrosinkinase-Inhibitor (TKI), der mehrere Rezeptor-Tyrosinkinasen und Nicht-Rezeptor-Tyrosinkinasen hemmt, darunter PDGF-Rezeptoren, FGF-Rezeptoren und VEGF-Rezeptoren.',
    usageGuidelines: 'Für wissenschaftliche Kommunikation, medizinische Fortbildung und Fachinformationen.',
    restrictions: [
      'Wirkmechanismus darf nicht vereinfacht werden',
      'Wissenschaftliche Genauigkeit erforderlich',
      'Geeignet für alle medizinischen Fachkreise'
    ],
    mlrNumber: 'MLR-OFEV-2024-DE-0025',
    approvalDate: '2023-11-28',
    expiryDate: '2025-11-28'
  }
];

// Helper functions
export const getOfevContentByMarket = (market) => {
  return OfevPreApprovedContent.filter(content => content.market === market);
};

/**
 * Helper function to get pre-approved content by category
 */
export const getOfevContentByCategory = (
  market,
  category
) => {
  return OfevPreApprovedContent.filter(
    content => content.market === market && content.category === category
  );
};

/**
 * Helper function to search content by keyword
 */
export const searchOfevContent = (market, keyword) => {
  const lowerKeyword = keyword.toLowerCase();
  return OfevPreApprovedContent.filter(
    content =>
      content.market === market &&
      (content.approvedContent.toLowerCase().includes(lowerKeyword) ||
        content.contentType.toLowerCase().includes(lowerKeyword))
  );
};